












Editorial / Commentary 
NEW PROGNOSTIC INDICATORS IN SURGERY 
Burcin Ekser, MD, PhD1, Massimiliano Veroux, MD, PhD2 
(1) Department of Surgery, Indiana University School of Medicine, Indianapolis, IN,
USA; (2) Department of Medical and Surgical Sciences, University of Catania, Catania, 
Italy.  
Address correspondence to: 
Burcin Ekser, MD, PhD 
Department of Surgery,  
Indiana University School of Medicine,  
550 University Blvd, Room 4601 
Indianapolis, IN, USA  
Telephone: 317-944-4370; Fax 317-948-3268 
Email: bekser@iupui.edu 
ORCID: 
Burcin Ekser  : 0000-0003-0741-8007 
Massimiliano Veroux : 0000-0002-2780-6421 
KEY WORDS: new prognostic factor, albumin-to-alkaline phosphatase ratio, surgery. 
(Word count: Text 493, Table 1) 
____________________________________________________
This is the author's manuscript of the article published in final edited form as: 















For more than 50 years, universally used laboratory values enable us to 
understand and assess the organ function, such as serum creatinine for kidney function, 
serum aspartate aminotransferase and alanine aminotransferase for liver function, and 
serum amylase and lipase for pancreas function. Examples can be increased for other 
organs. However, it is also known that several organs share common laboratory values, 
therefore differential diagnosis is very important before any interpretation will be done 
regarding the organ function based on single or multiple laboratory values (e.g., alkaline 
phosphatase [ALP] is produced by the liver and bones). Moreover, complex disorders, 
such as cancer, not only impact the involved organ(s) but also the entire metabolism 
including bone-muscle system as well as nutritional condition of the patient. Recent 
efforts included a search for new prognostic indicators to understand patient outcomes 
before any treatment is administered in patients with cancer, so the treatment can be 
personalized, tailored, or augmented for a better outcome. 
In the current issue of International Journal of Surgery, Li et al. [1] studied the 
impact of albumin-to-ALP ratio (AAPR) as a novel prognostic indicator for patients 
undergoing minimally invasive lung cancer surgery for non-small-cell lung cancer 
(NSCLC). The rationale of choosing AAPR to study the outcomes of NSCLC patients 
includes (i) albumin being a reliable indicator for patient’s nutritional condition and 
reflecting the host systemic inflammatory response, and (ii) ALP being the hydrolase 
converted in liver, bile duct, and kidneys, which is also being increasingly used as a 
predictor of mortality for cancer patients with distant metastasis [1,2].  
In recent years, AAPR has been used to evaluate patient outcomes/survival in 














cancer therapies [2], (ii) cholangiocarcinoma after surgery without pre-operative 
treatment [3], (iii) limited stage small-cell lung cancer before and after chemo-radiation 
therapy [4], (iv) non-metastatic nasopharyngeal carcinoma before radical radiotherapy 
[5], and (v) upper tract urothelial carcinoma (Table 1). In all above-mentioned cancer 
types, AAPR was found valuable prognostic indicator to assess the patient outcome 
with or without surgery [1-5]. Furthermore, some studies also included propensity score 
matched analysis in order to augment the statistical power minimizing confounders and 
confirming again AAPR as a valuable prognostic indicator [1,5]. 
Although AAPR could be an attractive prognostic indicator in patients with 
various cancer types [1-5], attention should be paid to other factors that are universally 
known impacting the patient survival, such as cancer size, number of positive lymph 
nodes, patient age, other co-morbidities, etc, as also indicated by above-mentioned 
studies. Most importantly, considerations should be carefully handled since ALP existed 
in several isoforms which can originate from the liver and bones. In regard to 
isoenzymes of ALP, cancer patients could have a significant hazard for bone-related 
ALP which might challenge the true interpretation of AAPR. 
The true value of AAPR as a risk stratification tool in cancer patients should be 
assessed in prospective, multi-center studies whether the applicability of AAPR is valid 














Table 1: The use of albumin-to-alkaline phosphatase ratio in clinical studies. 
Year Disorder / Cancer Type Reference 
2018 Upper tract urothelial carcinoma # 
2018 Advanced hepatocellular carcinoma 2 
2019 Non-metastatic nasopharyngeal carcinoma 5 
2019 Cholangiocarcinoma 3 
2019 Small-cell lung cancer 4 
2019 Invasive (non-small cell) lung cancer 1 
Legend: (#) P. Tan et al. The prognostic significance of Albumin-to-Alkaline Phosphatase Ratio in upper 
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